Search - tctmd.com

Displaying 161 - 180 of 297

Sort: Relevancy | Date

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

Caitlin E. Cox

December 20, 2018

News Daily News

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Caitlin E. Cox

November 28, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

Todd Neale

October 15, 2018

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

L.A. McKeown

October 12, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Shelley Wood

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

$A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years$

News Daily News

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Yael L. Maxwell

August 10, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Advertisement

Many PCI Patients Treated in China Have No Angina Symptoms

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Once Again, ISCHEMIA Trial Feels the Squeeze

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content